Literature DB >> 15147156

Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor System.

Gerald Steinbach1, Bettina Rau, Anne-Lise Debard, Jean-François Javourez, Jacques Bienvenu, Antonio Ponzio, Andrea Bonfà, Walter Hubl, Thomas Demant, W R Külpmann, Jana Buchholz, Gerhard Schumann.   

Abstract

We compared the manually performed LUMItest procalcitonin (PCT) assay with the newly developed fully mechanized Kryptor PCT assay and determined the essential assay characteristics of this assay. The new Kryptor PCT assay was evaluated according to modified NCCLS EP-10/EP-6 protocols in five different laboratories. Samples from 696 patients were assayed using the original LUMItest PCT assay and the new Kryptor PCT assay. Possible interference by hemoglobin, triglycerides and bilirubin was evaluated by spiking patient plasma with the appropriate substances. The functional assay sensitivity (FAS) was determined by analyzing samples with low PCT concentrations. The FAS of the new Kryptor PCT assay was 0.04 ng/ml and the imprecision within- and between-series below 5% and below 10%, respectively. Within the smallest range of determination, from 0.3 ng/ml to 50 ng/ml, common to the LUMItest PCT assay (x) and the Kryptor PCT assay (y) the values correlated well: y=0.64+0.94x, s.xy=2.78 ng/ml. The performance characteristics of the Kryptor PCT assay are fully compatible with the intended clinical use. The assay allows determination of PCT in a turnaround time (TAT) of about 20 minutes and thus is adequate for STAT analyses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147156     DOI: 10.1515/CCLM.2004.077

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  24 in total

1.  Procalcitonin in hypoxic brain damage.

Authors:  Aisha Lateef; S M Khoo; K H Lee
Journal:  Intensive Care Med       Date:  2005-01-21       Impact factor: 17.440

Review 2.  Procalcitonin: present and future.

Authors:  H H Liu; J B Guo; Y Geng; L Su
Journal:  Ir J Med Sci       Date:  2015-07-10       Impact factor: 1.568

Review 3.  Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.

Authors:  Kenneth L Becker; Richard Snider; Eric S Nylen
Journal:  Br J Pharmacol       Date:  2009-11-27       Impact factor: 8.739

4.  Procalcitonin as the biomarker of inflammation in diagnosis of appendicitis in pediatric patients and prevention of unnecessary appendectomies.

Authors:  Vishal Chandel; Sajjid Hussain Batt; Mohammad Younis Bhat; Nadeem Ulnazeer Kawoosa; Adfar Yousuf; Babar Rashid Zargar
Journal:  Indian J Surg       Date:  2010-12-01       Impact factor: 0.656

5.  Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.

Authors:  David T Huang; Lisa A Weissfeld; John A Kellum; Donald M Yealy; Lan Kong; Michael Martino; Derek C Angus
Journal:  Ann Emerg Med       Date:  2008-03-17       Impact factor: 5.721

6.  The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia.

Authors:  Sachin Kale; Sachin Yende; Lan Kong; Amy Perkins; John A Kellum; Anne B Newman; Abbe N Vallejo; Derek C Angus
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

7.  Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin (PCT): a prospective international multicenter study.

Authors:  Bettina M Rau; Esko A Kemppainen; Andrew A Gumbs; Markus W Büchler; Karl Wegscheider; Claudio Bassi; Pauli A Puolakkainen; Hans G Beger
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

Review 8.  Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis.

Authors:  B Rau; C M Krüger; M K Schilling
Journal:  Langenbecks Arch Surg       Date:  2004-03-06       Impact factor: 3.445

Review 9.  The use of procalcitonin in the diagnosis of bone and joint infection: a systemic review and meta-analysis.

Authors:  C-J Shen; M-S Wu; K-H Lin; W-L Lin; H-C Chen; J-Y Wu; M C-H Lee; C-C Lee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-21       Impact factor: 3.267

10.  Salivary and serum procalcitonin and C-reactive protein as biomarkers of periodontitis in United States veterans with osteoarthritis or rheumatoid arthritis.

Authors:  R S Redman; G S Kerr; J B Payne; T R Mikuls; J Huang; H R Sayles; K L Becker; E S Nylén
Journal:  Biotech Histochem       Date:  2016       Impact factor: 1.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.